 Myelodysplastic Syndromes
"Myelodysplastic Syndromes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.
| Descriptor ID |
D009190
|
| MeSH Number(s) |
C15.378.190.625
|
| Concept/Terms |
Myelodysplastic Syndromes- Myelodysplastic Syndromes
- Myelodysplastic Syndrome
- Syndrome, Myelodysplastic
- Syndromes, Myelodysplastic
- Dysmyelopoietic Syndromes
- Dysmyelopoietic Syndrome
- Syndrome, Dysmyelopoietic
- Syndromes, Dysmyelopoietic
Hematopoetic Myelodysplasia- Hematopoetic Myelodysplasia
- Hematopoetic Myelodysplasias
- Myelodysplasia, Hematopoetic
- Myelodysplasias, Hematopoetic
|
Below are MeSH descriptors whose meaning is more general than "Myelodysplastic Syndromes".
Below are MeSH descriptors whose meaning is more specific than "Myelodysplastic Syndromes".
This graph shows the total number of publications written about "Myelodysplastic Syndromes" by people in this website by year, and whether "Myelodysplastic Syndromes" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1992 | 1 | 0 | 1 | | 1995 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2001 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 2005 | 1 | 0 | 1 | | 2007 | 1 | 1 | 2 | | 2008 | 2 | 0 | 2 | | 2009 | 0 | 1 | 1 | | 2010 | 2 | 1 | 3 | | 2011 | 1 | 0 | 1 | | 2012 | 3 | 0 | 3 | | 2013 | 1 | 1 | 2 | | 2014 | 4 | 2 | 6 | | 2015 | 5 | 1 | 6 | | 2016 | 4 | 5 | 9 | | 2017 | 6 | 0 | 6 | | 2018 | 10 | 0 | 10 | | 2019 | 4 | 2 | 6 | | 2020 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Myelodysplastic Syndromes" by people in Profiles.
-
Nakano TA, Lau BW, Dickerson KE, Wlodarski M, Pollard J, Shimamura A, Hofmann I, Sasa G, Elghetany T, Cada M, Dror Y, Ding H, Allen SW, Hanna R, Campbell K, Olson TS. Diagnosis and treatment of pediatric myelodysplastic syndromes: A survey of the North American Pediatric Aplastic Anemia Consortium. Pediatr Blood Cancer. 2020 10; 67(10):e28652.
-
Winters AC, Maloney KW, Treece AL, Gore L, Franklin AK. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia. Pediatr Blood Cancer. 2020 10; 67(10):e28398.
-
Stein EM, Fathi AT, DiNardo CD, Pollyea DA, Roboz GJ, Collins R, Sekeres MA, Stone RM, Attar EC, Frattini MG, Tosolini A, Xu Q, See WL, MacBeth KJ, de Botton S, Tallman MS, Kantarjian HM. Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial. Lancet Haematol. 2020 Apr; 7(4):e309-e319.
-
Myers KC, Furutani E, Weller E, Siegele B, Galvin A, Arsenault V, Alter BP, Boulad F, Bueso-Ramos C, Burroughs L, Castillo P, Connelly J, Davies SM, DiNardo CD, Hanif I, Ho RH, Karras N, Manalang M, McReynolds LJ, Nakano TA, Nalepa G, Norkin M, Oberley MJ, Orgel E, Pastore YD, Rosenthal J, Walkovich K, Larson J, Malsch M, Elghetany MT, Fleming MD, Shimamura A. Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study. Lancet Haematol. 2020 Mar; 7(3):e238-e246.
-
Zhang H, Wilmot B, Bottomly D, Dao KT, Stevens E, Eide CA, Khanna V, Rofelty A, Savage S, Reister Schultz A, Long N, White L, Carlos A, Henson R, Lin C, Searles R, Collins RH, DeAngelo DJ, Deininger MW, Dunn T, Hein T, Luskin MR, Medeiros BC, Oh ST, Pollyea DA, Steensma DP, Stone RM, Druker BJ, McWeeney SK, Maxson JE, Gotlib JR, Tyner JW. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis. Blood. 2019 09 12; 134(11):867-879.
-
Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, Jordan CT, Purev E. CD123 CAR T cells for the treatment of myelodysplastic syndrome. Exp Hematol. 2019 06; 74:52-63.e3.
-
Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, Jordan CT, Smith C, Pollyea DA. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. Leuk Res. 2019 06; 81:43-49.
-
Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, Jordan CT, Pietras EM, Alper S. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. Haematologica. 2019 09; 104(9):e388-e392.
-
Zhou KY, Wang YX, Zhang S, Gachloo M, Kim JD, Luo Q, Cohen KB, Xia JB. GOF/LOF knowledge inference with tensor decomposition in support of high order link discovery for gene, mutation and disease. Math Biosci Eng. 2019 02 20; 16(3):1376-1391.
-
Cortes JE, Heidel FH, Hellmann A, Fiedler W, Smith BD, Robak T, Montesinos P, Pollyea DA, DesJardins P, Ottmann O, Ma WW, Shaik MN, Laird AD, Zeremski M, O'Connell A, Chan G, Heuser M. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia. 2019 02; 33(2):379-389.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|